Dr. Allen Krantz reports

ADVANCED PROTEOME THERAPEUTICS REPORTS ON WARRANT EXERCISE

All of the 3.1 million share purchase warrants that were issued under Advanced Proteome Therapeutics Corp.'s private placement that closed on Nov. 5, 2013, having an expiry date of May 5, 2015, have been exercised by the holders to purchase 3.1 million common shares of the company at a price of 15 cents per share, for proceeds to the company of $465,000.

In addition to the amount above, the 248,000 finders' warrants issued under the private placement were exercised to purchase 248,000 common shares of the company at a price of 15 cents for $37,200, for aggregate gross proceeds to the company of $502,200.

"Our investors' confidence in APC is gratifying," said Dr. Allen Krantz, chief executive officer. "We will use these funds for aggressively testing our lead compounds in animal models of cancer to advance them in development, and to explore possibilities for partnering and business development. We recognize the importance of combining our expertise with our colleagues in industry to reap benefits for both patients and our investors, and exploring the possibilities of out licensing surplus technology, which are integral parts of the company's strategy."

We seek Safe Harbor.